NexImmune Analyst Ratings
NexImmune Analyst Ratings
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.45, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 11/15/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/16/2022 | 339.66% | Barclays | $7 → $2 | Maintains | Overweight |
| 08/16/2022 | 559.49% | Raymond James | $12 → $3 | Maintains | Outperform |
| 06/01/2022 | 999.14% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/01/2022 | 1438.8% | Barclays | $4 → $7 | Maintains | Overweight |
| 02/22/2022 | 2757.77% | Raymond James | $21 → $13 | Maintains | Outperform |
| 11/15/2021 | 4516.4% | Raymond James | $30 → $21 | Maintains | Outperform |
| 04/01/2021 | 6494.86% | Raymond James | → $30 | Initiates Coverage On | → Outperform |
| 03/09/2021 | 7594% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/16/2022 | — | 坎託·菲茨傑拉德 | 降級 | 超重 → 中性 | |
| 11/15/2022 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
| 08/16/2022 | 339.66% | 巴克萊 | 7 美元 → 2 美元 | 維護 | 超重 |
| 08/16/2022 | 559.49% | 雷蒙德·詹姆 | 12 美元 → 3 美元 | 維護 | 跑贏大盤 |
| 2022 年 1 月 6 日 | 999.14% | BTIG | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/01/2022 | 1438.8% | 巴克萊 | 4 美元 → 7 美元 | 維護 | 超重 |
| 02/22/2022 | 2757.77% | 雷蒙德·詹姆 | 21 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 11/15/2021 | 4516.4% | 雷蒙德·詹姆 | 30 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 2021 年 1 月 4 日 | 6494.86% | 雷蒙德·詹姆 | → 30 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 9 月 3 日 | 7594% | 坎託·菲茨傑拉德 | → 35 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for NexImmune (NEXI)?
nexImmune（NEXI）的目標價格是多少？
The latest price target for NexImmune (NASDAQ: NEXI) was reported by Cantor Fitzgerald on November 16, 2022. The analyst firm set a price target for $0.00 expecting NEXI to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年11月16日公佈了NexImmune（納斯達克股票代碼：NEXI）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計NEXI將在12個月內跌至12個月內（可能下跌-100.00％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for NexImmune (NEXI)?
分析師對nexImmune（NEXI）的最新評級是多少？
The latest analyst rating for NexImmune (NASDAQ: NEXI) was provided by Cantor Fitzgerald, and NexImmune downgraded their neutral rating.
坎託·菲茨傑拉德對NexImmune（納斯達克股票代碼：NEXI）的最新分析師評級由坎託·菲茨傑拉德提供，NexImmune下調了中性評級。
When is the next analyst rating going to be posted or updated for NexImmune (NEXI)?
NexImmune（NEXI）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NexImmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NexImmune was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與NexImmune的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。NexImmune的最新評級是在2022年11月16日公佈的，因此您應該預計下一個評級將在2023年11月16日左右公佈。
Is the Analyst Rating NexImmune (NEXI) correct?
分析師對nexImmune（NEXI）的評級是否正確？
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.45, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的NexImmune（NE****級已下調，目標股價爲0.00美元至0.00美元。NexImmune（NEXI）目前的交易價格爲0.45美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
